Switching the Histamine H2 Receptor Antagonist Famotidine to Nonprescription Status in Canada
- 1 January 1996
- journal article
- Published by Springer Science and Business Media LLC in PharmacoEconomics
- Vol. 9 (1), 61-75
- https://doi.org/10.2165/00019053-199609010-00007
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Self-Directed Treatment of Intermittent Heartburn: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Evaluation of Antacid and Low Doses of an H(2)-Receptor Antagonist (Famotidine).1995
- Reflections on a month in the life of the Ontario Drug Benefit Plan.1994
- Over-the-Counter Histamine H2-Receptor AntagonistsDrugs, 1994
- Efficacy of Twice Daily Doses of 40 or 20 Milligrams Famotidine or 150 Milligrams Ranitidine for Treatment of Patients with Moderate to Severe Erosive EsophagitisScandinavian Journal of Gastroenterology, 1993
- The costs and benefits of switching a drug from prescription-only to over-the-counter status: a review of methodological issues and current evidence.1992
- Famotidine in gastroesophageal reflux disease (GERD).1992
- Ranitidine for Non-Ulcer Dyspepsia: A Clinical Study of the Symptomatic Effect of Ranitidine and a Classification and Characterization of the Responders to TreatmentScandinavian Journal of Gastroenterology, 1991
- Cimetidine Use and Gastric CancerEpidemiology, 1990
- Over-the-Counter DrugsDrug Safety, 1990
- An approach to dyspepsia in the ambulatory care settingJournal of General Internal Medicine, 1989